A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Abstract Background Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI) that can affect patients’ health-related quality of life and cause disruptions to treatment. SWOG S1013 (NCT01416688) is a multi-center study designed to validate the Functional As...

Full description

Bibliographic Details
Main Authors: Siu-Fun Wong, Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries, Anna Moseley, Kathryn Arnold, Mario R. Velasco, Justin D. Floyd, Benjamin T. Esparaz, Afsaneh Barzi, Heinz-Josef Lenz, Marianna Koczywas, Shaker Dakhil, Gary V. Burton, Michael J. Fisch, N. Lynn Henry, Dawn L. Hershman, Carol M. Moinpour
Format: Article
Language:English
Published: SpringerOpen 2020-07-01
Series:Journal of Patient-Reported Outcomes
Subjects:
EGFRI
FACT-EGFRI 18
Dermatologic toxicity
Papulopustular rash
Patient-reported outcome measure
Health-related quality of life
Online Access:http://link.springer.com/article/10.1186/s41687-020-00220-x

Internet

http://link.springer.com/article/10.1186/s41687-020-00220-x

Similar Items